The Covid-19 pandemic highlighted the difficulties clinical trial sponsors face with recruiting suitable participants as well as high patient drop-out rates.
The direct-to-patient (DtP) model provides an alternative to the traditional method of recruiting for clinical trials, by enabling patients to receive treatments in their home or at another convenient location.
This Pharma IQ report, produced in collaboration with 4G Clinical, looks at how the DtP approach can improve recruitment and retention rates, which ultimately leads to improving the speed-to-market of the products being trialed.
Download this exclusive Pharma IQ report to discover:
- Why DtP can address the challenges oftraditional clinical trials
- How to ensure safety and regulatory requirements are met
- What digital technologies are enabling DtP